Premium
Neutral Endopeptidase Inhibitors and Atrial Natriuretic Peptide
Author(s) -
Achilihu Godfrey,
Frishman William H.,
Landau Andre
Publication year - 1991
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1991.tb03773.x
Subject(s) - neprilysin , atrial natriuretic peptide , endopeptidase , diuretic , natriuretic peptide , heart failure , medicine , pharmacology , npr2 , vasodilation , npr1 , cardiology , chemistry , enzyme , biochemistry
A limited number of ectoenzymes appear to be involved in the inactivation of circulating‐regulatory peptides. Neutral endopeptidase 24.11, a metallopeptidase, is known to inactivate atrial natriuretic peptide (ANP), a substance with diuretic, natriuretic, and vasodilatory effects. Synthetic inhibitors of endopeptidase 24.11, which can prolong the activity of ANP, are currently available. These agents are being evaluated as possible innovative therapies for patients with hypertension and congestive heart failure.